Anti-HMGI-C Antibodies for Rapid Aortic Dissection Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for acute aortic dissection (AAD) are delayed due to confusion with cardiac infarction symptoms, and there is a need for a specific biomarker to detect aortic wall damage in a timely manner, while HMGI-C plays a role in cancer metastasis and can serve as a cancer treatment target.
Innovation Solution
Development of antibodies that specifically bind to HMGI-C epitopes, allowing detection in body fluids and enabling rapid diagnostic tests for AAD and cancer using lateral flow devices, and therapeutic applications for HMGI-C-positive cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If current diagnostic methods are used for acute aortic dissection, then diagnosis can be made, but diagnosis is delayed due to confusion with cardiac infarction symptoms
Solution Approach 1:
The patent introduces HMGI-C as an intermediary biomarker that specifically indicates aortic wall damage. This mediator enables differentiation between AAD and cardiac infarction by providing a specific detection target that is not present in cardiac infarction, thereby resolving the diagnostic confusion and enabling timely diagnosis.
Solution Approach 2:
The patent extracts HMGI-C from the complex diagnostic process as a standalone specific biomarker. By isolating and detecting this single specific protein in body fluids, the diagnostic system can directly identify AAD without being confounded by overlapping symptoms with cardiac infarction, thus reducing diagnosis time and improving specificity.
2Measurement precision
If highly specific antibodies against HMGI-C are developed, then detection of all 4 subtypes of HMGI-C is achieved, but antibody development becomes a very difficult task
Solution Approach 1:
The patent develops antibodies that bind to conserved epitopes present in all 4 subtypes of HMGI-C. This universal antibody design allows a single antibody to detect all variants of the target protein, achieving broad detection capability without requiring separate antibodies for each subtype, thereby reducing development complexity while maintaining high specificity.
Solution Approach 2:
The patent performs preliminary identification and characterization of specific epitopes on HMGI-C before developing the antibodies. By pre-defining the target epitopes and selecting antibodies that specifically bind to these predetermined regions, the development process becomes more systematic and less complex, while ensuring high detection specificity for all HMGI-C subtypes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide high specificity and sensitivity for detecting HMGI-C in body fluids, facilitating early diagnosis of AAD and cancer, and offering a therapeutic approach for HMGI-C-positive cancers.
Implementation Method 1
antibodies that specifically bind HMGI-C
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3D
AI summary
The disclosure relates to an (isolated) antibody (or antibody fragment/antigen binding fragment thereof) binding to (human) HMGI-C (anti-HMGI-C-Antibody) as well the nucleic acid encoding such an antibody or host cells comprising these or pharmaceutical composition comprising the antibody. Preferred antibodies are binding to the epitopes of SEQ. ID NOs. 32, 33 or 34, especially the (monoclonal) antibodies that comprise in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 4; in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 14; or in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 24. Especially preferred are also the (monoclonal) antibodies that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 1 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 6; that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 11 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 16; that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 21 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 26. In addition, the disclosure relates to a lateral flow device for the detection of HMGI-C, especially the HMGI-C released during an event leading to an acute aortic syndrome/acute aortic dissection (AAS/AAD) or in relation to cancer in a sample of bodily fluid of a human/patient using an antibody of the disclosure or to the use of the antibody for the treatment of cancer or for cancer prevention by early detection of HMGI-C as a marker for cancer.